Insys Therapeutics Aktie
WKN DE: A1JC8P / ISIN: US45824V2097
09.12.2014 13:41:41
|
Insys Therapeutics: FDA Grants Orphan Drug Designation To LEP-ETU - Quick Facts
(RTTNews) - Insys Therapeutics Inc. (INSY) announced the U.S. FDA has granted orphan drug designation to its Liposome Entrapped Paclitaxel Easy to Use, or LEP-ETU, candidate for the treatment of gastric cancer.
Paclitaxel, a widely used chemotherapeutic agent, is active in a broad spectrum of malignancies. LEP-ETU is an improved formulation of paclitaxel. Insys acquired LEP-ETU during its merger in 2010 with NeoPharm.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Insys Therapeutics Incmehr Nachrichten
Keine Nachrichten verfügbar. |